Roughly ten in every hundred thousand adults per year rupture a brain aneurysm and survive the initial bleed, and roughly a third of those survivors go on to develop delayed cerebral ischemia driven by cerebral vasospasm in the days that follow. The standard-of-care drug for vasospasm, nimodipine, produces only marginal survival and disability benefit. The clinical territory is one of the higher-mortality categories in neurology.

The US Food and Drug Administration on 30 June 2026 granted Breakthrough Device Designation to a non-invasive neurostimulator targeting that specific complication. The device is the V-Link System from Aurenar, a St Louis medical technology company, and the FDA-scope indication is reduction of cerebral vasospasm in adults with aneurysmal subarachnoid hemorrhage (aSAH) as an adjunct to clinical management. MassDevice reported the designation on 30 June 2026; the underlying announcement traces to Aurenar and the Washington University in St Louis School of Medicine.

Aurenar was founded in 2023 and is led by Eric Leuthardt, MD, professor of neurosurgery at the Washington University School of Medicine and a long-standing figure in the brain-computer interface research community. Its chief medical officer is Anna Huguenard, MD, also of Washington University. Its chief technology officer is Jenna Gorlewicz, PhD; its chief operating officer is Jesse Wheeler, PhD; and its founding advisor is Jeff Dunn, JD. Named investors include BioGenerator Ventures, the Washington University Olin Business School faculty investor group, the National Science Foundation Neuro360 accelerator, and the Washington University Office of Technology Management. Total funding raised has not been publicly disclosed.

What V-Link actually is

V-Link is a transauricular vagus nerve stimulator, meaning a disposable earbud-form-factor device that delivers low-energy electrical pulses through the skin of the outer ear to reach a branch of the vagus nerve that innervates the ear region. Transauricular vagus nerve stimulation (taVNS) is an established modality with published research going back a decade and a half. Aurenar’s contribution is to point the taVNS substrate at a specific neurological emergency, aSAH, rather than at the depression, epilepsy, or inflammatory indications where earlier taVNS work has concentrated.

The clinical basis for the Breakthrough Designation is a randomised controlled trial published by Huguenard, Leuthardt and colleagues in the Journal of Neurosurgery in 2025, based on a single-institution cohort of twenty-seven aSAH patients at Barnes-Jewish Hospital and Washington University. Patients receiving taVNS in that trial showed more than a 40 per cent reduction in the incidence of moderate-to-severe cerebral vasospasm, no reported adverse events, lower inflammatory cytokines in cerebrospinal fluid, less 90-day functional disability on standard scales, and a 20 per cent reduction in 30-day hospitalisation cost. A second Aurenar-associated clinical study, NUVISTA, extends the taVNS approach to acute ischemic stroke driven by large vessel occlusion, with a 35-patient trial reporting reductions in inflammatory biomarkers as published in Springer’s Translational Stroke Research in 2025.

The V-Link device is disposable and delivered as a routine bedside intervention rather than a chronic implant. The FDA Breakthrough scope covers the aSAH-vasospasm indication only; Aurenar has publicly discussed additional indications including ischemic stroke and glycemic control, but those are separate development tracks and do not carry the Breakthrough Designation.

Where V-Link fits in the bioelectronic-medicine cohort

Transauricular vagus nerve stimulation is a specific technology inside the broader bioelectronic-medicine category that Inside BCI has been covering as an adjacency to intracortical BCI. SetPoint Medical uses an implanted vagus nerve stimulator for rheumatoid arthritis and inflammatory bowel disease. LivaNova uses an implanted vagus nerve stimulator for epilepsy and treatment-resistant depression. electroCore uses a hand-held transcutaneous vagus nerve stimulator (gammaCore) for migraine and cluster headache. Spark Biomedical uses a transcutaneous auricular vagus nerve stimulator (LUNA) for neonatal opioid withdrawal and adult opioid withdrawal. Aurenar’s V-Link is closest in form factor to Spark’s LUNA (both are auricular taVNS earbud devices) but points at a different clinical indication.

The V-Link Breakthrough Designation is not the first Breakthrough for the aSAH-vasospasm clinical target. Rapid Medical received FDA Breakthrough Designation in February 2022 for its Comaneci device, a mechanical embolisation-assist system used in the same patient population. The correct superlative for Aurenar’s designation is the first non-invasive neuromodulation Breakthrough Device Designation for cerebral vasospasm in aSAH; the first-Breakthrough-in-vasospasm framing is available to Comaneci.

What to watch

The first signal is the FDA regulatory pathway Aurenar elects for V-Link. Breakthrough Device Designation is a regulatory-priority classification, not an approval. Aurenar has publicly described a De Novo submission strategy targeting a commercial launch in the early 2030s; a De Novo submission would be the next verifiable dated milestone.

The second signal is a pivotal or confirmatory clinical trial larger than the 27-patient single-site trial that supports the current Breakthrough Designation. A multi-site trial with a pre-specified primary endpoint at a scale of hundreds of patients would convert the current single-institution result into a regulatory-grade file.

The third signal is Medicare and commercial-payor coverage discussions. Devices treating high-mortality neurology indications where standard-of-care is a poorly-effective drug are natural coverage candidates once approved, and the timing of coverage conversations relative to FDA review is a leading indicator for commercial launch speed. Aurenar has not publicly announced payor engagement.

The fourth signal is whether Eric Leuthardt’s other commercial vehicles, including the Washington University startup portfolio he sits on, produce additional bioelectronic-medicine ventures in adjacent indications. Leuthardt’s public research career has spanned invasive BCI (ECoG), non-invasive BCI, and now bioelectronic modulation, and Aurenar is his current highest-profile commercial position.

Sources

• Aurenar gets FDA breakthrough nod for noninvasive neuromod tech (MassDevice, 30 June 2026)
• Aid for brain bleed recovery receives FDA Breakthrough Device Designation (WashU Medicine press release, 30 June 2026)
• Aurenar corporate site
• Metis Innovative portfolio: Aurenar (investor context)
• Huguenard, Leuthardt et al. aSAH taVNS randomised controlled trial (Journal of Neurosurgery, 2025)
• NUVISTA ischemic-stroke taVNS trial (Translational Stroke Research, 2025)
• Rapid Medical Comaneci FDA Breakthrough Device Designation, February 2022 (prior art for the aSAH-vasospasm clinical target)
• Inside BCI: CVRx Humana Medicare Advantage Barostim coverage, 16 May 2026 · Orchestra BioMed AVIM Therapy, 27 April 2026 · Motif Neurotech RESONATE IDE, late April 2026